We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biodynamics Plc | LSE:OBD | London | Ordinary Share | GB00BD5H8572 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.09 | 1.12% | 8.13 | 80,528 | 16:35:01 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 8.10 | 8.16 | 8.10 | 8.10 | 8.10 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 1.34M | -10.83M | -0.0535 | -1.51 | 16.27M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:34:44 | AT | 5,750 | 8.10 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/7/2024 | 07:00 | UK RNS | Oxford BioDynamics PLC OBD pursuing EpiSwitch as companion diagnostics |
| 21/6/2024 | 15:42 | UK RNS | Oxford BioDynamics PLC Grant of Options |
| 18/6/2024 | 16:58 | ALNC |  Oxford BioDynamics revenue up 49% in first half as test sales rise |
| 18/6/2024 | 07:00 | UK RNS | Oxford BioDynamics PLC Half-year Report |
| 06/6/2024 | 07:00 | UK RNS | Oxford BioDynamics PLC OBD's PSE test to be used in NCI trial |
| 04/6/2024 | 10:28 | ALNC | Oxford BioDynamics develops canine cancer test with 89% accuracy |
| 04/6/2024 | 07:00 | UK RNS | Oxford BioDynamics PLC OBD develops multi-cancer diagnostic test for dogs |
| 24/5/2024 | 07:00 | UK RNS | Oxford BioDynamics PLC Notice of Results |
| 23/5/2024 | 21:08 | ALNC | TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact |
| 23/5/2024 | 07:00 | UK RNS | Oxford BioDynamics PLC OBD partners with Goodbody Clinic on PSE test |
Oxford Biodynamics (OBD) Share Charts1 Year Oxford Biodynamics Chart |
|
1 Month Oxford Biodynamics Chart |
Intraday Oxford Biodynamics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 23/7/2024 | 19:48 | OBD without the muppets | 231 |
| 06/6/2024 | 07:44 | Oxford BioDynamics PLC | 1,687 |
| 15/1/2024 | 20:55 | OBD-23/03/21-110P-SP might go up exponentially given the potential in the US | 52 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 14:34:44 | 8.10 | 5,750 | 465.75 | AT |
| 2024-07-26 14:34:38 | 8.10 | 5,550 | 449.55 | O |
| 2024-07-26 14:30:21 | 8.10 | 33,000 | 2,673.00 | AT |
| 2024-07-26 14:30:17 | 8.10 | 17,500 | 1,417.50 | O |
| 2024-07-26 13:32:57 | 8.10 | 2,207 | 178.77 | O |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Oxford Biodynamics Daily Update Oxford Biodynamics Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker OBD. The last closing price for Oxford Biodynamics was 8.04p.Oxford Biodynamics currently has 202,303,415 shares in issue. The market capitalisation of Oxford Biodynamics is £16,386,577. Oxford Biodynamics has a price to earnings ratio (PE ratio) of -1.51. This morning OBD shares opened at 8.10p |
Posted at 23/7/2024 19:48 by pj84 "tevevubes" I presume is "the revenues" and "1w" months of cash is presumably "12" months.I agree just over 12 months of cash if nothing happens and I expect we have about 6 months or so before the issue of funds starts to become an issue again. The trades over the past week or so seem to suggest selling but the price movement suggests there is buying or a buy being filled. |
Posted at 17/7/2024 21:18 by pj84 It looks like the MRC meeting dates might have been on 3 and 4 July.If so, 10 working days from 4 July would be 18 July and if successful OBD should be notified tomorrow with possibly an RNS tomorrow or the day after. |
Posted at 22/6/2024 00:00 by pj84 Obviously it's a free bet and the worst that can happen for the CEO is that the bet lapses without ever being exercised.But with 10m share options it clearly incentives the CEO. If he doubles the share price from the fund raise to 18p he stands to benefit by nearly £1m. Not sure why you have chosen OBD to share your wisdom on, as as far as I can see, the last 10 pages (could be more) of your posting history seems to be solely on the "Flat Earth" thread and the "New World order" thread, neither of which appear to be investment threads? But each to there own. |
Posted at 21/6/2024 20:58 by pj84 Good to see that the CEO's 10m share options are tied in to the performance of the shares relative to the recent fund raise, as he only benefits if the share price exceeds 9p, and the more the share price exceeds 9p the more he and those who invested in the fund raise stand to gain. Looking more like a partnership deal would benefit all shareholders as well as the CEO. |
Posted at 18/6/2024 22:56 by pj84 There are significant risks and so far I have taken a small position in OBD, particularly as the potential for the PSE test is huge.There is no guarantee the rate of increase in tests will grow as quickly as I hope, but I hope it does and that could lead to an increase in share price and the potential for raising at a higher price and I will be interested to see the update in early October. However, if you listened to the webinar update today you will have heard that for both the PSE and CiRT tests OBD isn't stubbornly going to try and avoid partnerships with big companies with deep pockets and big distribution networks and they are prepared to explore partnerships that could have an upfront payment, with milestone payments and royalties and the CEO said that a lower upfront payment tied to milestone payments to tie in with the interests of a partner would be attractive looking at the growing royalties on the market penetration a big partner could open up. I hope that is what they manage to do. |
Posted at 20/2/2024 01:11 by bones698 At the end of the day they need to turn it into money and a profitable business and thus far are failing to do that. Many companies struggle at this stage to turn promise into cash and when they are so. Loss making like obd it means they are required to raise capital at ever lower prices. In this market that resits in an share price that gets hammered and ehyvobd is struggling as everyone knows its coming.Getting a deal with a large upfront payment at this stage is unlikely but a small one won't provide enough runeya to see a profit and so a rights issue is the most likely outcome at a big discount given the amount they are likely to require. Sad but true for many small companies atm |
Posted at 19/1/2024 20:43 by bones698 I doubt they have enough time to construct such a deal as they can take upto a year to complete and they need funds for sooner than that . Unfortunately that then means a fund raise on the open market is most likely and that will be at a discount . The market seems to agree with this and is marking the price down accordingly . The longer they leave it to do the lower the share price and rights issue price is likely to be . Judging by the shareprice they might have already approached the market so anywhere from 10-15p fund raise looks likely as it's not stopped falling yet . Funders also tend to forward sell the shares to recoup their money that way . |
Posted at 08/12/2023 10:10 by bigruss1 Oxford, UK - 2 AUGUST 2023 - Oxford BioDynamics PLC (AIM: OBD, "OBD", the "Company" and, together with its subsidiaries, the "Group"), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, is pleased to announce that it has successfully raised gross proceeds of £5.6m pursuant to a placing, conducted via an accelerated bookbuild process (the "Placing") and through direct subscriptions (the "Subscription").Conditionally, in aggregate, 48,120,790 new ordinary shares of 1p ("Ordinary Shares") each in the Company will therefore be issued pursuant to the Placing (the "Placing Shares") at an issue price of 11p per new Ordinary Share ("Issue Price"). The Placing comprised both a General Placing and a VCT/EIS Placing. Subscribers have conditionally subscribed for, in aggregate, 2,528,634 new Ordinary Shares (the "Subscription Shares") at the Issue Price. In addition, retail investors are able to participate via the PrimaryBid platform (the "PrimaryBid Offer", and together with the Placing and the Subscription, the "Fundraising"). The PrimaryBid Offer remains open. Further details on the results of the PrimaryBid Offer will be announced separately. The Placing Shares and Subscription Shares represent approximately 25.7 per cent. of the Company's issued ordinary share capital as enlarged by the Placing and Subscription. Shore Capital and Baden Hill acted as joint brokers and bookrunners in connection with the Placing. Its clear to me there is still alot of share to flip and the downward trend will continue unlucky really for those spiked here ..Big sell off under way |
Posted at 26/10/2023 15:46 by smithie6 Blah blah blah.OBD has not created a yes/no test for prostate cancer. Full stop. If it had its share price would be much higher. ....if potential shareholders need to first have a degree in human pharma stuff & read the OBD test reports & understand words like "epigenetic biomarkers" Then the number of potential shareholders in the UK where OBD is listed is quite small. I'm not interested to devote the time to learn about all this medical jargon such as "epigenetic biomarkers". I note the words genetic & surveillance of people that have been tested. If OBD come up with a yes/no test for prostate cancer then I would be interested to again buy/hold some shares. ----- Usual low quality of posts on ADVFN. 'you don't like the shares so I'm going to slag you off' Infers that some posters are not very shrewd/wise. |
Posted at 03/10/2023 17:57 by czar OBD will make at least £500 per test, that is profit not sales and is after all costs. Agreed the NHS will get a discount but there is demand for 8m tests in the UK and OBD will have no capacity for the UK for quite a while and even then only 200,000 pa which is 2.5% of the tests required. By the time OBD is serving the NHS they will be doing millions of tests in the USA and millions more around the world. There will be plenty of US companies trying to buy OBD out long before they get that far. I just hope it doesn't get sold cheap like so many great British companies. Even after the rise over the last few days this company is valued at a fraction of its true worth IMHO. Anyway BUY it, SELL it, do whatever, people on here will make no difference to this share price. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
